|Mr. David F. Novack||Interim Co-Pres & Co-Principal Exec. Officer||614.59k||N/A||1962|
|Dr. Dennis A. Carson Ph.D., M.D.||Co-Founder, Director & Member of Scientific Advisory Board||40k||N/A||1947|
|Mr. Michael S. Ostrach||CFO, Chief Bus. Officer & Sr. VP||658.51k||N/A||1952|
|Dr. Robert L. Coffman||Chief Scientific Officer & Sr. VP||724.28k||N/A||1947|
|Dr. Robert Janssen||Chief Medical Officer & Sr. VP of Clinical Devel., Medical and Regulatory Affairs||656.81k||N/A||1954|
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Its product candidates include SD-101, a cancer immunotherapy that is in Phase 2 clinical trials; DV281, an investigational TLR9 agonist, which is in Phase I clinical trial for the treatment of non-small cell lung cancer; and AZD1419, which is in Phase IIa clinical trial to treat asthma. Dynavax Technologies Corporation has a collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.
Dynavax Technologies Corporation’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 8; Compensation: 6.